Testing effectiveness (Phase 2)Looking for participantsNCT06568939
What this trial is testing
Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Who this might be right for
Non-Small Cell Lung Cancer
AbbVie 150